In English | En español
Questions About Cancer? 1-800-4-CANCER

Genetics of Prostate Cancer (PDQ®)

  • Posted: 11/20/2003
  • Updated: 09/30/2014

Table 12. Case-Control Studies of BRCA1 and BRCA2 and Survival Outcomes

Study Population Controls Prostate Cancer–Specific Survival Overall Survival Comments 
CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen.
Tryggvadóttir et al. (2007) [23]30 men diagnosed with prostate cancer who were BRCA2 999del5 founder mutation carriers59 men with prostate cancer matched by birth and diagnosis year and confirmed not to carry the BRCA2 999del5 mutationBRCA2 999del5 mutation was associated with a higher risk of death from prostate cancer (HR, 3.42; 95% CI, 2.12–5.51), which remained after adjustment for tumor stage and grade (HR, 2.35; 95% CI, 1.08–5.11).Not assessed
Edwards et al. (2010) [26]21 men diagnosed with prostate cancer who harbored a BRCA2 mutation: 6 with early-onset disease (≤55 y) from a UK prostate cancer study and 15 unselected for age at diagnosis from a UK clinical series1,587 age- and stage-matched men with prostate cancerNot assessedOverall survival was lower in BRCA2 mutation carriers (4.8 y) than in noncarriers (8.5 y); in noncarriers, HR, 2.14 ( 95% CI, 1.28–3.56; P = .003).
Gallagher et al. (2010) [16]832 AJ men diagnosed with localized prostate cancer between 1988 and 2007, of which there were 6 BRCA1 mutation carriers and 20 BRCA2 mutation carriers454 AJ men with no history of cancerAfter adjusting for stage, PSA, Gleason score, and therapy received:Not assessedThe BRCA1 5382insC founder mutation was not tested in this series.
BRCA1 185delAG mutation carriers had a greater risk of death due to prostate cancer (HR, 5.16; 95% CI, 1.09–24.53; P = .001).
BRCA2 6174delT mutation carriers had a greater risk of death due to prostate cancer (HR, 5.48; 95% CI, 2.03–14.79; P = .001).
Thorne et al. (2011) [27]40 men diagnosed with prostate cancer who were BRCA2 mutation carriers from 30 familial breast cancer families from Australia and New Zealand97 men from 89 familial breast cancer families from Australia and New Zealand with prostate cancer and no BRCA mutation found in the familyBRCA2 carriers were shown to have an increased risk of prostate cancer–specific mortality (HR, 4.5; 95% CI, 2.12–9.52; P = 8.9 × 10-5), compared with noncarrier controls.BRCA2 carriers were shown to have an increased risk of death (HR, 3.12; 95% CI, 1.64–6.14; P = 3.0 × 10-4), compared with noncarrier controls.There were too few BRCA1 carriers available to include in the analysis.
Castro et al. (2013) [28]2,019 men diagnosed with prostate cancer from the United Kingdom, of whom 18 were BRCA1 mutation carriers and 61 were BRCA2 mutation carriers1,940 men who were BRCA1/2 noncarriersProstate cancer–specific survival at 5 years:Overall survival at 5 years:For localized prostate cancer, metastasis-free survival was also higher in controls than in mutation carriers (93% vs. 77%; HR, 2.7).
BRCA1: 80.8 (95% CI, 56.9–100)BRCA1: 82.5 (95% CI, 60.4–100)
BRCA2: 67.9 (95% CI 53.4–82.4)BRCA2: 57.9 (95% CI, 43.4–72.4)
– Controls: 90.6 (95% CI 88.8–92.4)– Controls: 86.4 (95% CI, 84.4–88.4)

References

  1. Gallagher DJ, Gaudet MM, Pal P, et al.: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16 (7): 2115-21, 2010.  [PUBMED Abstract]

  2. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, et al.: Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99 (12): 929-35, 2007.  [PUBMED Abstract]

  3. Edwards SM, Evans DG, Hope Q, et al.: Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103 (6): 918-24, 2010.  [PUBMED Abstract]

  4. Thorne H, Willems AJ, Niedermayr E, et al.: Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 4 (7): 1002-10, 2011.  [PUBMED Abstract]

  5. Castro E, Goh C, Olmos D, et al.: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31 (14): 1748-57, 2013.  [PUBMED Abstract]